Cynthia Mundy, Ph.D. and Melissa Stolper, therapeutic area directors at Decision Resources, are available to discuss the impact of today's alert from Biogen Idec and Genentech on their drug Rituxan.

The alert warned that two patients using Rituxan have died of a rare brain infection, the same one that shadows Biogen Idec and Elan's multiple sclerosis treatment Tysabri. In a letter sent to doctors, Biogen Idec and Genentech Inc. warned that the two patients had contracted fatal progressive multifocal leukoencephalopathy, or PML. Both patients were being treated for lupus, a disease in which Rituxan use is still considered experimental. The drug is approved only for use in rheumatoid arthritis and non-Hodgkin's lymphoma, a form of blood cancer, but doctors are allowed to prescribe it for other diseases at their discretion.

  Dr. Mundy and Ms. Stolper can provide:     - Background on the types of lupus patients who are candidates for      Rituxan treatment and implications for Rituxan's likely role in      treating the disease    - Analysis on how the market forecast for lupus may change in light of      the recent PML news    - Insight on how the rheumatoid arthritis drug market will be impacted by      the news    - Expert opinion on how safety issues will influence uptake of novel      immunomodulatory drugs  

To talk with Dr. Mundy or Ms. Stolper, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   781-296-2563 

PRNewswire - Dec. 19
First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Stem Cell and Bone Growth Factor Products Drive Orthopedic Biomaterials Market Growth

View Now